Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules

Pharmacological Research

Volumn 46, Issue 2, 2002, Pages 185-190

  Sempere Ortells, J M ^a   Campos, A ^b   Velasco, I ^b   Marco, F ^a   Ramirez Bosca, A ^c   Diaz, J ^c   Pardo, J ^c  

^a UNIVERSITY OF ALICANTE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c ASAC Pharma   (Spain)

Author keywords

Adhesion molecules; Flow cytometry; Lymphocytes; Polypodium leucotomos; Proliferation

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; PADGEM PROTEIN; POLYPODIUM LEUCOTOMOS EXTRACT; GLYCOSIDE; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPAIN; T LYMPHOCYTE ACTIVATION; BLOOD; CD4 LYMPHOCYTE COUNT; CELL ADHESION; CELL AGGREGATION; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANTIGENS, CD; CD4 LYMPHOCYTE COUNT; CELL ADHESION; CELL AGGREGATION; GLYCOSIDES; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 0036421523     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1043-6618(02)00091-9     Document Type: Article

References (25)

1. Vasange-Tuominen M, Perera-Ivarsson P, Shen J, Bohlin L, Rolfsen W. The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid constituents as inhibitors of leukotriene B4 formation. Prostaglandins Leukot Essen Fatty Acids 1994; 50: 279-84.
2. Rayward J, Villarrubia VG, Guillen C, Prieto A, Rodriguez-Zapata M, Sada G, Alvarez-Mon M. An extract of the fern Polypodium leucotomos, inhibits human peripheral blood mononuclear cells proliferation in vitro. Int J Immunopharmacol 1997; 19: 9-14.
3. Mohammad A. Vitiligo repigmentation with Anapsos Polypodium leucotomos. Int J Dermatol 1989; 28: 479.
4. Navarro F, Sempere JM. Modification of the inflammatory activity of psoriatic arthritis in patients treated with extract of Polypodium leucotomos. Br J Rheumatol 1998; 37: 912-7.
5. Alvarez A, Pichel V, Pérez P, Laredo M, Zas R, Fernández-Novoa L, Sempere JM, Díaz J, Cacabelos R. Double blind, randomized, placebo controlled pilot study with Anapsos in senile dementia: Effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Methods Find Exp Clin Pharmacol 2000; 22: 585-94.
6. Vargas J, Muñoz C, Osorio C, García-Olivares E. Anapsos, an antipsoriatic drug which increases the proportion of suppresor cells in human peripheral blood. Ann Inmunol (Inst Pasteur) 1983; 134: 393-400.
7. Bernd A, Ramírez-Bosca A, Huber H, Díaz J, Thaci D, Sewell A, Quintanilla E, Holzmann H. Immunomodulating effects of Polypodium leucotomos extract on human leukocytes in vitro. Drug Res 1995; 45: 901-4.
8. Alvarez A, Franco A, Zas R, Sempere JM, Díaz J, Cacabelos R. Interleukin-1 overexpression and behavioural deficits in NBM-lesioned rats: Reversion with Anapsos. Methods Find Exp Clin Pharmacol 1997; 19: 299-309.
9. Sempere JM, Rodrigo C, Campos A. Effects of Anapsos (Polypodium leucotomos extract) on in vitro production of cytokines. Br J Clin Pharmacol 1997; 43: 85-9.
10. Beltrán R, Mateo M, Ascensión P. Precomunicación sobre un nuevo tratamiento efectuado con 48 niños afectados de dermatitis atópica. Actual Dermatol 1982; 10: 52-5.
11. Piñeiro Alvarez B. Dos años de experiencia personal en el tratamiento con Anapsos del psoriasis en diferentes formas clíinicas (495 casos). Antolog Dermatog 1982; 11: 45-51.
12. Jiménez D, Naranjo R, Doblare E, Muñoz C, Vargas JF. Anapsos an antipsoriatic drug, in atomic dermatitis. Allergol Immunopathol 1987; 15: 185-9.
13. López M, Vargas JF. Anapsos, una nueva orientación terapéutica en las manifestaciones digestivas del estado atópico. Acta Pediatr Esp 1988; 46: 556-61.
14. Horvath A, Alvarado F, Szöcs J, De Alvarado ZN, Padilla G. Metabolic effects of Calagualine, an antitumoral saponine of Polypodium leucotomos. Nature 1967; 214: 1256-8.
15. Alvarez A, Miguel JJ, Fernández L, Sempere JM, Díaz J, Cacabelos R. Anapsos: Neuroimmunotrophic treatment in Alzheimer disease and neurodegenerative disorders. CNS Drug Rev 1997; 3: 181-205.
16. Fernández L, Alvarez XA, Sempere JM, Miguel JJ, Díaz J, Franco A, Cacabelos R. Effects of Anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration. Methods Find Exp Clin Pharmacol 1997; 19: 99-106.
17. Giorgi JV Immune cell phenotyping by flow cytometry. In: Rose NR, Conway E, Fahey J, Friedman H, Penn G, eds. Manual of Clinical Laboratory Immunology. 4th Edn. Washington, DC: American Society for Microbiology, 1992: 156-73.
18. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
19. Cuellar C, Rodero M, Bolas F, Martínez AR. The effects of Polypodium leucotomos extract on the specific antibody production patterns in Balb/c mice immunized with third stage larvae antigens of Anisakys simplex. Int J Pharmacognosy 1997; 35: 1-8.
20. Dea M, Rodero M, Rodríguez R, Bolas F, Martínez AR. Modulation by Anapsos (Polypodium leucotomos extract) of the antibody responses against the nematode parasite Trichinella spiralis. Phytother Res 1999; 13: 566-70.
21. Kishimoto T, Rothlein R. Adhesion molecules which guide neutrophil-endotelial cell interactions at sites of inflammation. In: Gupta S, Griscelli C, eds. New Concepts in Immunodeficiency Diseases. 1st Edn. Chichester, England: Wiley, 1993: 131-56.
22. Alpers JH, Frew J, Bradding P, Holgate ST. Extrinsic allergic asthma: Cellular recruitment and adhesion molecules. In: Bradley J, Mc-Cluskey J, eds. Clinical Immunology. New York: Oxford University Press Inc, 1997: 86-107.
23. Carreño MM, Castro P. Fenotipo inmunológico y tratamiento con Polypodium leucotomos en pacientes con esclerosis múltiple. Neurología 1994; 10: 509.
24. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, Döcke WD. Influence of monomethylfumarate on monocytic cytokine formation - Explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997; 289: 623-30.
25. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.